Company Overview - Seto Bio was established on January 19, 2010, and listed on the Shenzhen Stock Exchange on January 6, 2017. The company is headquartered in Heze, Shandong Province. It is the first domestic producer to scale the production of steroid drug raw materials using biotechnology, holding a leading position in this field [1]. Business Performance - In Q3 2025, Seto Bio reported revenue of 749 million yuan, ranking 22nd among 47 companies in the industry. The top company, Prolo Pharmaceutical, had revenue of 7.764 billion yuan, while the industry average was 1.466 billion yuan [2]. - The net profit for the same period was -79.1285 million yuan, placing the company 45th in the industry. The leading company, Zhejiang Pharmaceutical, reported a net profit of 867 million yuan, with the industry average at 133 million yuan [2]. Financial Ratios - As of Q3 2025, Seto Bio's debt-to-asset ratio was 37.15%, higher than the previous year's 35.26% and above the industry average of 27.75% [3]. - The gross profit margin for Q3 2025 was 12.53%, significantly lower than the previous year's 26.38% and below the industry average of 35.38% [3]. Executive Compensation - The chairman, Mi Qi, received a salary of 960,000 yuan in 2024, which remained unchanged from 2023. Mi Qi has held various positions within the company since 2014 and currently serves as chairman [4]. Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 7.91% to 13,700, while the average number of circulating A-shares held per shareholder decreased by 7.33% to 13,600 [5].

Core Viewpoint - The 2025 High-Quality Development Forum for Listed Companies and the 27th Golden Bull Award Ceremony took place in Nantong, Jiangsu, highlighting the importance of transparency and investor relations in the capital market [1][4]. Group 1: Company Overview - Saito Bio focuses on the research and production of steroid drug intermediates, leveraging gene engineering and microbial transformation technologies [4]. - The company has achieved large-scale application of biopharmaceutical technology in the steroid drug sector through years of independent research and technology introduction [4]. Group 2: Awards and Recognition - The Golden Bull Award is a prestigious evaluation event organized by China Securities Journal, emphasizing transparency and professionalism in the capital market [4][5]. - The awards include categories such as "Most Investment Value Award," "Golden Bull Outstanding Entrepreneur Award," and "Golden Bull Secretary Award," with the latter recognizing outstanding performance in corporate governance and investor relations [5]. Group 3: Investor Relations - Saito Bio has prioritized information disclosure and investor relations management since its listing, actively engaging with investors through various channels and timely responses [4]. - The company has received positive feedback from investors for its commitment to transparency and effective communication [4].

Core Insights - Saito Bio (300583.SZ) released its Q3 2025 report on October 29, 2025, indicating a total institutional holding of 43.2974 million shares, representing 22.82% of the company's total equity [1] Institutional Holdings - As of October 28, 2025, there is one institutional investor holding shares in Saito Bio, which is Shandong Runxin Investment Co., Ltd. [1] - The total institutional holding percentage decreased by 0.45 percentage points compared to the previous quarter [1] Public Fund Information - In this reporting period, 32 public funds were not disclosed compared to the previous quarter, including funds such as Guojin Quantitative Multi-Factor A, Guojin Quantitative Selected A, and others [1]

Core Insights - The company reported a revenue of 749 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 2.07% [1] - The net loss attributable to shareholders of the listed company was 69.23 million yuan [1] - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 72.39 million yuan [1] - The basic loss per share was 0.36 yuan [1]

山东赛托生物科技股份有限公司 证券代码：300583 证券简称：赛托生物 编号：2025-040 关于 2025 年前三季度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、本次计提资产减值准备情况概述 （一）本次计提资产减值准备的原因 根据《企业会计准则》《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等有关规定，为真实、准确反映公司的财务状况，公司基 于谨慎性原则，对合并报表范围内截至 2025 年 9 月 30 日的存货、应收款项、固定 资产、无形资产、商誉等资产进行了全面清查和减值测试，对合并报表范围内可能 发生资产减值损失的有关资产计提相应减值准备。 （二）本次计提资产减值准备的资产范围、总金额和计入的报告期间 经公司及下属子公司对报告期末存在减值迹象的各类资产，范围包括存货、应 收款项、固定资产、无形资产、商誉等，进行全面清查和减值测试后，计提 2025 年 前三季度各项资产减值准备合计 40,591,741.96 元，具体明细如下： 单位：元 | 项 目 | 资产减值计提金额 | | --- ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥241,425,650.02, representing a year-on-year increase of 21.70%[4] - The net profit attributable to shareholders was -¥16,543,142.49, a significant decline of 1,199.98% compared to the same period last year[4] - The basic earnings per share for Q3 2025 was -¥0.08, reflecting a decrease of 900.00% year-on-year[4] - The total profit for the year-to-date was -¥75,201,207.54, a decline of 462.69% compared to the same period last year[9] - Net profit for the period was a loss of ¥79,128,524.62, compared to a profit of ¥13,200,659.89 in the previous period, indicating a significant decline[19] - Operating profit turned negative at -¥74,138,162.11, down from a positive ¥21,181,969.70 in the prior year[19] - Basic and diluted earnings per share were both -¥0.36, compared to ¥0.08 in the previous period[20] Cash Flow - The cash flow from operating activities for the year-to-date was ¥77,809,222.82, down 53.96% from the previous year[4] - The net cash flow from operating activities was $77.81 million, a decrease of 54% compared to $169.01 million in the previous period[22] - Cash inflow from operating activities totaled ¥553,336,844.67, down from ¥607,886,012.30, a decrease of approximately 8.9% year-over-year[21] - Cash outflows from operating activities totaled $475.53 million, compared to $438.87 million in the prior period[22] - The net cash flow from investing activities was -$27.43 million, an improvement from -$61.30 million year-over-year[22] - Cash inflows from investment activities totaled $10.52 million, significantly higher than $2.36 million in the prior period[22] Assets and Liabilities - Total assets at the end of Q3 2025 were ¥2,866,079,082.42, a decrease of 5.28% from the end of the previous year[4] - Total current assets decreased from 1,284,916,162.65 CNY to 1,189,810,971.39 CNY, a decline of approximately 7.41%[14] - Total assets decreased from 3,025,806,782.53 CNY to 2,866,079,082.42 CNY, a decline of approximately 5.26%[14] - Total non-current assets decreased from 1,740,890,619.88 CNY to 1,676,268,111.03 CNY, a decline of approximately 3.71%[14] - The total liabilities decreased to ¥1,064,836,700.02 from ¥1,141,641,832.99, a reduction of approximately 6.7%[19] - Total equity attributable to shareholders decreased to ¥1,766,097,218.21 from ¥1,839,121,540.57, a decline of about 4.0%[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,737[11] - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 22.82% of shares, totaling 43,297,382 shares, with 7,440,000 shares pledged[11] - The second-largest shareholder, Mi Chaojie, holds 20.62% of shares, totaling 39,116,800 shares[11] Investment and Expenses - The company experienced a 50.40% decrease in investment income, totaling ¥5,391,355.27 for the year-to-date[8] - Research and development expenses were ¥32,249,551.03, down from ¥41,391,541.00, reflecting a reduction of about 22.1%[19] - Cash paid to employees was $83.66 million, down from $107.49 million year-over-year[22] - Cash paid for taxes was $23.87 million, a decrease from $40.83 million in the previous period[22] - Cash paid for the acquisition of fixed assets was $34.96 million, down from $63.66 million year-over-year[22] Credit and Impairment - The company reported a 514.07% increase in credit impairment losses, amounting to -¥9,637,137.21 for the year-to-date[8] - The company reported a credit impairment loss of -¥9,637,137.21, compared to a gain of ¥2,327,445.50 in the previous period[19]

Group 1 - Dongfang Caifu announced that shareholders plan to transfer a total of 237.8 million shares at a price of 24.40 yuan per share, with 32 institutional investors participating in the bidding [1] - Laofengxiang's subsidiary plans to invest 24 million USD to acquire a 20% stake in Maybach Luxury Goods Asia Pacific, becoming the second-largest shareholder [1] - Saito Bio's subsidiary received a CEP certificate for Dexamethasone Sodium Phosphate, allowing it to sell in international markets [2] Group 2 - Jianglong Shipbuilding is expected to win a bid for a 600-ton fishery enforcement vessel project worth 72.99 million yuan, accounting for 4.22% of its audited revenue for 2024 [3] - Shikong Technology is planning to acquire control of Shenzhen Jiahe Jinwei Electronic Technology Co., Ltd., with stock trading suspended for up to 5 trading days [4] - Mould Technology's controlling shareholder plans to reduce its stake by up to 1% due to funding needs [5] Group 3 - Guokong Electronics expects a net profit increase of 64.72% to 80.17% for the first three quarters of 2025, with projected revenue of 340 million to 370 million yuan [7] - Beimo High-Tech anticipates a net profit increase of 50% to 60% for the same period, with a projected net profit of 125 million to 133 million yuan [8] - ST Haofeng's controlling shareholder has transferred 15.0046% of shares to Zhixin Network at a price of 6 yuan per share, totaling 331 million yuan [9] Group 4 - ST Changyuan's major shareholder plans to reduce its stake by up to 3% within 90 days due to risk management [11] - Runze Technology's shareholder plans to reduce its stake by up to 1% due to personal funding needs [12] - Limin Co. expects a net profit increase of 649.71% to 669.25% for the first three quarters of 2025, with a projected net profit of 384 million to 394 million yuan [14] Group 5 - Kanda New Materials received a government subsidy of 10.05 million yuan, accounting for 4.08% of its latest audited net profit [15] - Keheng Co.'s shareholder plans to reduce its stake by up to 1% due to personal funding needs [16] - New Hope reported a September sales revenue of 1.746 billion yuan from 1.3942 million pigs sold, with a year-on-year decline of 23.82% [18] Group 6 - Wan'an Technology plans to invest 150 million yuan to establish a joint venture in Wuhan for automotive chassis systems [19] - Wan'an Technology also intends to acquire a 40% stake in Fuao Wan'an for 26.22 million yuan, aiming for full ownership [19] - Kuai Ke Electronics' controlling shareholder plans to transfer 4% of the company's shares through an inquiry [20] Group 7 - Changan Automobile's joint venture Avita Technology has completed payment of 3.45 billion yuan for a 10% stake in Huawei's Yiwang [21]

Core Viewpoint - The company Saito Bio (300583.SZ) announced that its subsidiary Shandong Sry Pharmaceutical Co., Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) for the active pharmaceutical ingredient Dexamethasone Sodium Phosphate [1] Group 1: Company Developments - Saito Bio's subsidiary, Shandong Sry Pharmaceutical, has been granted a CEP certificate for Dexamethasone Sodium Phosphate, indicating compliance with European pharmacopoeia standards [1] - Dexamethasone Sodium Phosphate is a corticosteroid with anti-inflammatory, anti-allergic, anti-rheumatic, and immunosuppressive properties [1] Group 2: Product Applications - The drug is primarily used for treating allergic and autoimmune inflammatory diseases, including connective tissue diseases, active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, severe dermatitis, ulcerative colitis, and acute leukemia [1] - It is also utilized in the comprehensive treatment of certain severe infections, poisoning, and malignant lymphomas [1]

Core Viewpoint - Saito Bio's subsidiary, Shandong Sry Pharmaceutical Co., Ltd., has received the CEP certificate for Dexamethasone Sodium Phosphate from the European Directorate for the Quality of Medicines (EDQM), enhancing its position in the pharmaceutical market [1] Company Summary - Saito Bio's subsidiary, Shandong Sry Pharmaceutical, applied for the CEP certificate for Dexamethasone Sodium Phosphate in April 2024 and received it in October 2025 [1] - The drug Dexamethasone Sodium Phosphate is a corticosteroid with anti-inflammatory, anti-allergic, anti-rheumatic, and immunosuppressive properties, primarily used for allergic and autoimmune inflammatory diseases [1] Industry Summary - There are a total of 9 companies globally that hold valid CEP certificates for Dexamethasone Sodium Phosphate, including Shandong Sry Pharmaceutical [1]

证券代码：300583 证券简称：赛托生物 编号：2025-038 山东赛托生物科技股份有限公司 关于子公司收到化学原料药欧洲CEP证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）控股子公司山东斯瑞 药业有限公司（以下简称"斯瑞药业"）近日收到欧洲药品质量管理局（以下简 称"EDQM"）签发的原料药欧洲药典适用性证书（以下简称"CEP 证书"），现将 相关情况公告如下： 一、原料药注册批件信息 化学原料药名称：DEXAMETHASONE SODIUM PHOSPHATE 地塞米松磷酸钠 药品生产商/持有人：山东斯瑞药业有限公司 生产地址：山东省菏泽市定陶区东外环路南段 证书编号：CEP 2025-180-Rev 00 发证机关：欧洲药品质量管理局（EDQM） 有效期：自 2025 年 10 月 1 日起五年内有效 二、原料药的相关情况 地塞米松磷酸钠是一种肾上腺皮质激素类药，具有抗炎、抗过敏、抗风湿以 及免疫抑制作用，主要用于过敏性与自身免疫性炎症性疾病，多用于结缔组织病、 活动性风湿病、类风湿性关节 ...